AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research HANGZHOU, China and NEW YORK, June 26, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets,...

Chinese Center for Drug Evaluation (CDE) Cleared Taletrectinib IND and Issued Clinical Trial Authorizations for Two Phase 2 Clinical Trials in China HANGZHOU, China, March 23, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today announced...